ANDA 210226, held by Lupin. Dimethyl Fumarate.
As of Nov 21, 2026, ANDA 210226 (Dimethyl Fumarate), held by Lupin, was first approved by FDA on Oct 6, 2020, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2020 | Original application | Approved | None posted |
| Dimethyl Fumarate120MG ยท capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Dimethyl Fumarate240MG ยท capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Jan 14, 2025 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Feb 16, 2024 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Feb 16, 2024 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Feb 16, 2024 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Feb 16, 2024 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Oct 6, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters